

IN THE CLAIMS:

1. (Currently amended) An isolated peptide which has from 13 to 60 amino acids, and which comprises SEQ ID NO: 1, wherein the isolated peptide possesses trypanolytic activity as determined by a trypanolytic assay.

2. (Currently amended) An isolated or recombinant peptide comprising the amino acid sequence of SEQ ID NO: 3 or a fragment thereof having trypanolytic activity as determined by a trypanolytic assay.

3. (Canceled) The isolated peptide of claim 1 exhibiting trypanolytic activity.

4. (Withdrawn) An antibody specifically recognizing a peptide selected from the group consisting of a peptide comprising at least 9 contiguous amino acids of SEQ.ID.NO.1, a peptide comprising the amino acid sequence of SEQ.ID.NO.3, a fragment of either thereof, and an epitope of either thereof.

5. (Withdrawn) A DNA sequence encoding an Eisenia foetida protein or polypeptide or encoding an immunologically active and/or functional fragment thereof selected from the group consisting of:

- (a) DNA sequences comprising a nucleotide sequence encoding a protein or peptide comprising the amino acid sequence as given in SEQ ID NO. 1 or 3;
- (b) DNA sequences comprising a nucleotide sequence as given in SEQ ID NO: 2;
- (c) DNA sequences hybridizing with the complementary strand of a DNA sequence as defined in (a) or (b) and encoding an amino acid sequence which is at least 80% identical to the amino acid sequence encoded by the DNA sequence of (a) or (b);
- (d) DNA sequences the nucleotide sequence of which is degenerated as a result of the genetic code to a nucleotide sequence of a DNA sequence as defined in any one of (a) to (c); and
- (e) DNA sequences encoding a fragment of a protein encoded by a DNA sequence of

any one of (a) to (d).

6. (Withdrawn) A recombinant expression vector comprising the DNA sequence of claim 5.

7. (Withdrawn) A host cell transformed or transfected with an expression vector according to claim 6.

8. (Withdrawn) The host cell of claim 7 wherein the host cell is selected from the group consisting of *E. coli*, *Bacillus sp.*, *Streptomyces sp.*, yeast, fungi, insect cells, plant cells and mammalian cells.

9. (Withdrawn) The host cell of claim 8, wherein the host cell is *E. coli*.

10. (Withdrawn) A process for the production of an *Eisenia foetida* polypeptide or an immunologically active or functional fragment thereof comprising culturing a host cell of claim 7 under conditions allowing the expression and production of said polypeptide and recovering the thus produced polypeptide from the culture.

11. (Currently amended) A ~~pharmaceutical~~ composition comprising a peptide selected from the group consisting of: an isolated peptide which has from 13 to 60 amino acids and which comprises SEQ ID NO: 1, wherein the isolated peptide possesses trypanolytic activity as determined by a trypanolytic assay; an isolated or recombinant peptide comprising SEQ ID NO: 3, wherein the isolated or recombinant peptide possesses trypanolytic activity as determined by a trypanolytic assay; a fragment of either thereof having trypanolytic activity as determined by a trypanolytic assay, and an epitope of either thereof.

12. (Withdrawn) A method of treating a disease selected from the group of diseases consisting of trypanosomal infection, bacterial infection and cancer, said method comprising:
administering a peptide selected from the group of peptides consisting of a peptide

comprising at least 9 contiguous amino acids of SEQ.ID.NO.1, a peptide comprising the amino acid sequence of SEQ.ID.NO.3, a fragment of either thereof, and an epitope of either thereof.

13. (Canceled)

14. (Withdrawn) The process according to claim 10, wherein the host cell is selected from the group consisting of *E. coli*, *Bacillus sp.*, *Streptomyces sp.*, yeast, fungi, insect cells, plant cells, and mammalian cells.

15. (Withdrawn) The process according to claim 14, wherein the host cell is *E. coli*.

16. (Currently amended) The ~~pharmaceutical~~ composition of claim 11, wherein the peptide comprises at least 9 contiguous amino acids of SEQ ID NO: 1, a fragment thereof having trypanolytic activity as determined by a trypanolytic activity, or an epitope thereof.

17. (Currently amended) The ~~pharmaceutical~~ composition of claim 11, wherein the peptide is the amino acid sequence of SEQ ID NO: 3, a fragment thereof having trypanolytic activity as determined by a trypanolytic assay, or an epitope thereof.

18. (Withdrawn) The method according to claim 12 wherein the peptide comprises at least 9 contiguous amino acids of SEQ.ID.NO.1 a fragment thereof, or an epitope thereof.

19. (Withdrawn) The method according to claim 12 wherein the peptide comprises the amino acid sequence of SEQ.ID.NO.3, a fragment thereof, or an epitope thereof.

20. (Currently amended) An isolated or recombinant peptide having a sequence selected from the group consisting of SEQ ID NO: 1, an amino acid sequence which has from 13 to 60 amino acids and which comprises SEQ ID NO: 1, a recombinant amino acid sequence comprising SEQ ID NO: 3, and a fragment of the recombinant amino acid sequence comprising SEQ ID NO: 3 having trypanolytic activity as determined by a trypanolytic assay.

21. (Previously presented) An isolated peptide consisting of SEQ ID NO: 1.
22. (Previously presented) An isolated or recombinant peptide consisting of SEQ ID NO: 3.
23. (New) An isolated peptide consisting essentially of SEQ ID NO: 1, wherein the isolated peptide possesses trypanolytic activity as determined by a trypanolytic assay.
24. (New) An isolated or recombinant peptide consisting essentially of SEQ ID NO: 3 or a functional fragment thereof, wherein the isolated or recombinant peptide or functional fragment thereof possesses trypanolytic activity as determined by a trypanolytic assay.
25. (New) A method for producing a peptide, the method comprising:
producing a peptide consisting essentially of SEQ ID NO: 1, wherein the peptide exhibits trypanolytic activity as determined by a trypanolytic assay
26. (New) The method according to claim 25, wherein producing the peptide comprises expressing a nucleic acid encoding the peptide consisting essentially of SEQ ID NO: 1.
27. (New) The method according to claim 26, wherein the peptide comprises SEQ ID NO: 3.
28. (New) The method according to claim 25, wherein producing the peptide consisting essentially of SEQ ID NO: 1 comprises shortening a full length CCF-1 protein.